Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus

下一代表型抗菌药物敏感性测试平台：快速结果和全面的菜单

基本信息

批准号：
10325484
负责人：
ERIC STERN
金额：
$ 100万
依托单位：
SELUX DIAGNOSTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10325484
关键词：
Address Adopted Adoption American Antibiotic Resistance Antibiotic susceptibility Antibiotics Antimicrobial Resistance Antimicrobial susceptibility Benchmarking Biological Assay Blood Clinical Clinical Medicine Communicable Diseases Computer software Data Diagnostic Epidemic Evaluation Feedback Freezing Funding Future Goals Gold Health Healthcare Infection Laboratories Lead Letters Longevity Manuals Methods Molds Multi-Drug Resistance Oral Patient Care Patients Performance Pharmaceutical Preparations Phase Phenotype Positioning Attribute Price Process Readiness Reagent Reference Standards Reflex action Sampling Site Small Business Innovation Research Grant Sonication System Test Result Testing Time Universities Work accurate diagnosis antimicrobial base combat cost cost effectiveness design improved individual patient next generation novel performance tests rapid diagnosis recruit usability

项目摘要

The goal of this CRP SBIR proposal is to fund four projects to advance the commercial readiness of Selux’s rapid, comprehensive, low-cost, phenotypic antibiotic susceptibility test (AST) system. Selux’s next-generation phenotyping (NGP) platform uniquely enables rapid AST with comprehensive antimicrobial menus of >50 drugs at a low cost from isolates and positive blood culture samples. Aims 1 and 2 focus on cost reduction projects important for early customer adoption. Aim 1 comprises analytical studies to support multiplex oral panels and Aim 2 is a DFM redesign of the Analyzer consumable pack. Aims 3 and 4 focuses on work necessary for later customer adoption. Aim 3 is a yearlong benchmarking study that will compare Selux NGP performance against legacy AST systems and reference methods. By improving system workflows and benchmarking AST performance across legacy systems CRP funding will help position Selux NGP as the dominant AST platform of the future.

该CRP SBIR提案的目标是资助四个项目以推进广告 Selux快速，全面，低成本，表型抗生素易感性的准备就绪测试（AST）系统。 Selux的下一代表型（NGP）平台唯一可以快速 AST与50种药物的全面抗菌男性，分离株的低成本和阳性血液培养样品。目的1和2关注降低成本项目对早期很重要客户采用。 AIM 1包括分析研究，以支持多重口头面板和AIM 2是分析仪消耗包的DFM重新设计。目标3和4专注于工作以后的客户采用所必需的。 AIM 3是一年的基准研究将SELUX NGP性能与遗产AST系统和参考方法进行比较。经过改善系统工作流程和基准测试范围内的遗留系统CRP的AST性能资金将有助于将Selux NGP定位为未来的主要AST平台。